Tremendous Progress with Adult Stem Cells in 2007

The FDA approved clinical trials for adult stem cells to the tune of 1100 in 2006. But 2007 was even more successful for adult stem cells. Over 1400 FDA approved trials for 73 different conditions in humans where patient health has been improved through adult stem cell therapy were documented in peer-reviewed studies in 2007.

Umbilical cord blood, placentas, and other tissues in the body contain adult stem cells. They are found throughout the entire body. No embryos are destroyed when extracting adult stem cells, which is in contrast with the extraction of embryonic stem cells.

We have decided to publish a yearly update each fall/winter since treatments with adult stem cells are continually increasing and continue to be impressive. (Note: Embryonic stem cells have never produced successful treatment trials in humans.)

Adult stem cells do not create tumors, unlike embryonic stem cells.

The research and treatments involving adult stem cells has been fast paced since our 2006 paper, thus, we have summarized some of the developments in the field below.

The Regeneration of Heart Tissue

Eight years ago, Doug Rice was diagnosed with congestive heart failure. Due to his diabetes, he was unable to get a heart transplant.

Rice decided to travel offshore for adult stem cell treatment since he was facing fatal heart failure. Stem cells were extracted from a sample of blood taken from Rice. The cells were differentiated into angiogenic cell precursors, then transplanted into Rice’s heart.

The results were immediate for Rice, who experienced an increase in his hearts efficiency of 30 percent. He originally had an ejection fraction of 11 percent.

According to Rice, “I’ve been around a lot of people with bad hearts. I know if they looked at [adult stem cell therapy], it might save their lives. I firmly believe it saved mine.”

A few other companies have developed adult stem cell technology for heart patients.

Marc Penn, director of the Bakken Heart Brain Institute at the Cleveland Clinic, says of one new therapy, “It’s very exciting, perhaps a sea-changing trial for the field … offering the chance of an off-the-shelf-product.”

Bone marrow stem cells have been used by Bodo-Eckehard Strauer to treat over 300 heart patients. He is the director of the cardiology department at Dusseldorf University Hospital. A patient who was

MS Patient Improves Following Adult Stem Cell Treatment

Without the ability to even walk a short distance, Cathy Zuker suffered from Multiple Sclerosis for 27 years. Her condition had progressed to an absolute worse case scenario.

Before she got a stem cell transplant, she had to lift her legs manually when she got into the car. Her left leg would drag behind her when she walked. Her condition started improving after a stem cell transplant on May 21st, 2007. She began to notice a difference in her legs on the 24th. She said her legs started to feel lighter on the 25th, and considered her improvement to be amazing. On June 7th, 2007, she was able to not only move her legs but could get into a car without any help. Not only that, but her energy returned as well.

According to her,

Non-Profit Public Stem Cell Bank Opens in Chennai

Providing high quality stem cells for treatment, a Public Stem Cell Bank will be established in Chennai by the non-profit Jeevan Blood Bank company.

On Thursday, Dr. P. Srinivasan, Chairman, told reporters that about 40,000 units of stem cells collected from cord blood would be collected, processed and stored by the stem cell bank in five years. The project is set to go live before the end of March 2008.

Blood cancers, heart disease, autism, and more than 70 other medical conditions can be treated and potentially cured by stem cells. It is one of the best treatment options available today.

Srinivasan said the bank plans to collect cord blood from donors, harvest stem cells, test for transmissible infections, store and ultimately release the safe compatible units to any one who needs them across the world.

By December of 2008, completion if accreditation processes by international agencies is planned for the Jeevan Stem Cell Bank.

Private storage at the bank will be fee based. The funding would then be applied to the public side of the bank in order to pay for those services. 30 percent of the available storage has been reserved for private banking, while the other 70 percent is reserved for public storage.

So that matching units of cord blood can be identified by any hospitals across India as well as the world, the bank plans to publish the contents of a stem cell registry online in the next 12 weeks. When a suitable unit of stem cell was available, it would be transported frozen to the hospital where the patient was admitted for transplantation, he said.

By April 2009, the facility will be moved to a permanent 25,000 square feet location. In the meantime, it will operate on rental premises said Srinivasan.

MS and ALS Adult Stem Cell Progress Made in Israel

By injecting sufferers of neurological diseases with therapeutic quantities of cultured adult stem cells, scientists based at Jerusalem’s Hadassah University Hospital have broken new ground in the field of stem cell research.

The researchers extracted stem cells from the hip bone marrow of 26 multiple sclerosis (MS) and amytrophic lateral sclerosis (ALS) patients. The cells were re-injected into the patients via lumbar puncture following a two-month long process of in vitro cleansing, multiplication and chemical ‘tagging’. The researcher team was led by Professor Dimitrious Karussis and Prof. Shimon Slavin, the recently retired head of Hadassah’s bone marrow unit.

The particular type of stem cell used in the trial, marked a world first according to Karussis.

“The sole aim of this study was to explore the feasibility and the safety of this treatment, since it is applied for first time,” Karussis told ISRAEL21c.

The experiment was deemed a success with no adverse effects reported. Leading the way for further developments in forthcoming clinical trials, it was encouraging that patients also displayed anecdotal improvements in clinical symptoms.

“Most MS patients reported a stabilization of their condition and some an improvement in function, especially in sphincter control, muscle power in arms, tremor and stability in walking,” Karussis said. “ALS patients continued to show signs of deterioration – though at a lesser than previous degree.”

This is good news for both groups of patients. Resulting in impaired sensory, motor, balance and vision function, MS causes damage to the body’s central nervous system and affects over 2.5 million people worldwide. Causing the gradual and fatal loss of the patient’s capacity for movement, ALS or Lou Gehrig’s disease, involves a similar degeneration of neuronal cells. ALS is more rare and progresses more rapidly.

Both conditions are ideal targets for stem cell treatment since they are both caused by the deterioration of a specific type of cell.

Suggesting that it might be possible to regenerate damaged nervous systems through cell re-growth, the Hadassah researchers found that transplanted adult stem cells began to differentiate into the kinds of cells which the diseases had destroyed. This was observed during extensive experimentation on animal models of MS and ALS.

Despite suffering from a similar motor neuron disorder, the treated lab mice retained 90 percent of their neurons after the equivalent of one or two years in the human progression of the diseases.

Marking the first time such adult stem cells have been injected into human patients, Karussis cited the most recent safety study. The study has paved the way for a larger efficacy trial to be held over the course of the next few years, despite remaining highly experimental since the small-scale study lacked a control group.

“We are encouraged as these are patients with advanced cases, many of them in wheelchairs,” Karussis told the Jerusalem Post.

Since most of the attention in recent years has been directed towards embryonic stem cell research, the current work utilizing adult stem cells is significant say scientists. There are advantages to using adult cells. The chances of immune rejection are significantly reduced since the patient can serve as his or her own donor. The ethical issues which surround embryonic stem cells is also avoided with this approach.

The researchers hope to launch a controlled clinical trial of the therapies after first enlarging the safety study to include more patients. Applications from potential trial patients are a welcome sight.

However, a license must first be obtained from the Ministry of Health, as well as funding to cover the expense of treating patients; a cost that can be up to $20,000 per patient. Despite these significant challenges, the team says it will all be worthwhile in the long run.

Stem cells, Karussis notes, “have already shown some promise in the treatment of joint and bone diseases, immune conditions and ischemia of the heart.” And he is optimistic, he says, that MS and ALS will join that auspicious list one day “not far into the future.”

28 Heart Failure Patients Treated with Adult Stem Cells

Using autologous stem cells, 28 patients were recently treated for acute myocardial infarction (MI) at the Sir Hurkisondas Nurrotumdas (HN) Hospital in Mumbai, India. The Medical Research Society of HN Hospitals funded the research. Patients from the 39-68 years age group were chosen for the project which was started in June of 2005.

“Most attempts including ours have considered the adult bone marrow as the source of the repair stem cells which is a source of hematopoietic and stromal stem/progenitor cells and have demonstrated that the implantation procedure is safe, feasible and effective in terms of improving the myocardial salvage rate of the infarcted myocardium. The latter can be attributed to the angiogenic events or secretion of angiogenic cytokines by these cells,” said Dr. VK Shah, Principal Investigator and Interventional Cardiologist, HN Hospital.

Facilitating the ability of the heart to heal itself, patient’s own bone marrow stem cells reach the infarcted area with the blood supply and contribute to the restoration of stem cell niches. The patient’s cells are injected into the culprit coronary artery after the opening of the occlusion by primary angioplasty.

“All the cases were successful without any complications. This procedure is done while the patient is fully conscious,” Dr. Shah claimed.

Further explaining the process, Dr. Shah said, “We have completed clinical check-up of all the patients of two, four, six and twelve weeks. Further a six-month follow-up of left ventricular (LV) function assessment by LV angiography and cardiac magnetic resonance imaging in stem cell therapy group have demonstrated an increase in LV ejection fraction (EF) by 7-12 per cent as compared to 1-3.2 per cent controls. There is improvement in LV systolic function, wherein LV end systolic volume (LVESV) has decreased significantly to 16-28 per cent. No patient has demonstrated deterioration of regional wall motion or any other side effects during the follow-up period. The results of our study show favourable trend towards improvements of cardiac functions which is the key determinant for long-term survival.”

In order to see what the long term effects of bone marrow infusion on any organ are, the hospital has carried out some routine tests at the end of two years. Normal in all patients were; lipid profile, renal function tests, liver function test, chest X-ray, sonography of abdomen and blood tests which include complete haemogram, ECG, and 2D echocardiography. The detailed clinical evaluation was performed on all patients starting with the first who received bone marrow stem cell therapy.

“In addition to the regular clinical follow-up, these tests helped us in assessing the safety and feasibility of transfusing autologous bone marrow stem cells (ABMSC) into the culprit coronary artery after an acute anterior wall MI,” said Dr. Shah.

According to patient Rajaram Chandra Jagdale (54), who underwent the therapy last April after suffering from an acute MI, “I am doing fine after the therapy.”

Mechanism Behind Muscle Stem Cell Transformation Discovered

Costa Rica is the destination for a seven year old boy named Matthew from Central Florida. The boy and his family are traveling not for a vacation, but with the hope of curing the boys autism, which was diagnosed when he was 18 months old.

“He wasn’t born with autism,” Matthew’s father Daniel Faiella said.

Matthew began to lose his ability to speak as he got older.

The future of medicine could potentially be revolutionized because of stem cells. This very reason has kept scientists working night and day all over the world in an effort to better understand the mechanisms that ensure the self-renewal of these cells and their capability to treat human disease.

With an active role in replacing dying cells and regenerating tissue, somatic stem cells, which are better known as adult stem cells, can be found in the human body. With such high therapeutic potential, these cells have become the subject of numerous research studies because of their ability to self-renew and generate cells identical to those of the organ from which they originate.

Via bone marrow transplant, various types of blood and bone cancers such as leukemia have already been treated using adult stem cells. The U.S. Government has given more research funds to institutes who study adult stem cells since they don

Sacramento Man Treated for Spinal Injury Using Own Stem Cells

Leaving him hobbled and unable to work for nearly three years, Perry Anderson’s spine injury has changed the man’s life considerably. But stem cells are now being implanted into his spine and may work wonders in repairing his spine from a surgery that failed the first time.

The stem cells being used are not from human embryos. They come from bone marrow, and they not only have the potential to heal Perry’s spine, but the same type of cells allow diabetics to continue producing insulin, end the suffering caused be inflammatory bowel disease, and help heart attack patients heal.

Bone marrow stem cells, harvested both from cadavers and from live donors, are being developed for use against a range of illnesses. This is all while the ethical debate rages over the use of stem cells taken from discarded human embryos.

To control diseases caused by the sometimes harmful effects of the body’s own immune system these cells are proving useful in experimental drug therapies and have exhibited a remarkable ability to form fat, cartilage, ligaments, bone and tendons.

An adult stem cell-based drug is being tested at UC Davis by stem cell scientist Jan Nolta. She will be treating patients with Crohn’s, a chronic and painful bowel disease. Also using the cells in spine surgery, is the Sacramento based Dr. Pasquale Montesano.

Found in the tissue tucked inside the bone cavity are MSC’s, or mesenchymal stem cells.

Kept frozen, MSC’s can be stored for up to five years. But they must be used within 48 hours once removed in order to remain viable.

Anderson’s stem cells arrived in a tiny jar carefully packed in dry ice and stored in a foam cooler on Thursday in the operating room at Sutter Memorial Hospital in Sacramento.

Back in 2004, Anderson fell from a 6-foot ladder while he was painting. This resulted in an injured back. Searing headaches and pain were the symptoms of a bad disk pinching a nerve in his neck. In August of 2006, he had surgery to remove the damaged disk and fuse the vertebrae. But the procedure was not 100% successful.

“The headaches aren’t as bad, but my hands get numb, my arms are aching, I have lower back pain, anxiety attacks and depression,” Anderson, 42, said before his surgery Thursday. “I have worked since I was 17. Now I can’t do anything. I can’t mow the yard, I can’t go grocery shopping. It’s ridiculous.”

Careful to avoid Anderson’s carotid artery and spinal cord, Montesano first removed the scar tissue and bony fragments from between the damaged vertebrae.

He then took the crystal-like stem cell and packed them into a graft made from cadaver bone and shaped like a square nut from a hardware store. He tucked more cells around the graft after gently placing it into Anderson’s spine.

By screwing a small metal plate into his spine to anchor the bone in place while it heals, Montesano completed Anderson’s operation.

“Now we have to let Mother Nature take its course,” he said.

A handful of companies worldwide are currently taking mesenchymal stem cells from live donors in order to develop drugs. In Japan, researchers are studying the treatment of severe gum disease, England is working on multiple sclerosis, and in Iran, scientists are looking for a way to use MSC’s to treat cirrhosis.

Rationalizing the Stem Cell Debate

Stem cell research, particularly the type involving embryos, has been a hot topic responsible for a high amount of writing, discussion, and media attention as of late.

With the power to repair and even replace damaged tissue and cells, stem cells, although very meager in looks, are the most remarkable building blocks in our bodies.

Stem cells which have been derived from sources which include blood, bone marrow, fat, umbilical cord blood, nerves, adult tissue, and even the pulp of baby teeth have amassed data; proving their success in the treatment of numerous conditions and diseases.

These cells are often called “adult stem cells”. Heart damage, Parkinson’s Disease, spinal cord injury, autism, diabetes are among the nearly 80 conditions which have been successfully treated using these adult cells.

In fact, since the active ingredient in the bone marrow is stem cells, thousands of lives have been saved by adult stem cells in the form of bone marrow transplants for leukemia and other illnesses alone.

A stem cell can make any number of cells with more specialized functions, or make a copy of itself. The cell starts as an unspecified cell and changes when it divides.

For example, depending on what the body needs, white bloods cells, red blood cells, or other kinds can be created from just one type of stem cell in the human blood.

To this day, not one single human patient has ever been cured or successfully treated with embryonic stem cells, thus, it is a wonder why there is so much hype surrounding embryonic stem cell research. Especially given the fact that adult stem cells have produced such gleaming results thus far. and will undoubtedly continue to do so well into the future.

Embryonic stem cell are not only ineffective, but dangerous. In animal tests, subjects have experienced immune system rejection, formed lethal tumors, and displayed genetic instability.

At the expense of advancing adult stem cell research, why does the media, culture, and society continually support embryonic stem cell research? The scientific validity of adult stem cell being vastly superior to embryonic cells is undeniable.

The answer is green.

Money, and extremely large amounts of it are floating around embryonic stem cell research. The ongoing attempts to obtain our tax dollars for this purpose, the billions that are already invested privately, even the basic cost of donated eggs for embryonic research; all this money has been wasted thus far at the expense of advancing and producing more treatments that save human lives.

However, the current querulous embryonic stem cell debate may soon be at an end thanks to the recent announcements by Japan’s Shinya Yamanaka and James A. Thomson at the University of Wisconsin. The two scientists made two separate discoveries involving skin cells. They were able to produce embryonic stem cell equivalents without the use of an embryo.

Why continue research on such a controversial issue when such an important breakthrough has been made? Embryonic stem cell research should be a non-issue at this point.

Supporters Growing for iPS Cell Breakthrough

Without the slightest bit of knowledge as to what is possible, probable, or even feasible, politicians will ask us to allocate billions for stem cell research. We were told that embryonic stem cells were the only answer for treating diabetes, MS, blindness, Parkinson’s, spinal cord injury, and heart disease. But the truth is that embryonic stem cells have failed in every single category. Successful treatments do exist for these conditions, but they are all derived from adult stem cells, which are non-controversial, and non-embryonic.

With what could be considered the most important medical advancement in history coming to fruition as we debate on ethics, it is sad that we don’t receive non-selective, factual, and accurate news. With all the important breakthroughs that are taking place, it is amazing that the public is being kept in the dark.

Stunning the entire research community last week, revered embryonic scientific stem cell leader Ian Wilmut (cloner of Dolly the sheep) made an announcement in support of adult stem cells over embryonic. His decision was based on solid scientific principal as opposed to religious or moral preference. Professor Wilmut has always maintained that there is a better way to accomplish the objective without destroying the embryo; in fact, he has never believed embryonic research to be unethical.

Despite the resistance of governments to fund embryonic stem cell research in the U.S. and England, the rest of the world has been conducting unrestricted research for more than ten years using embryos. Despite the joint efforts of Germany, India, Korea, Russia, and China who invested billions in research, not even one successful treatment was produced. This fact was made painfully obvious by neurologist Dr. Carlos Lima earlier this year when he was addressing the House of Lords in England.

Miracle Stem Cell Heart Repair, a breakthrough book by author/researcher Christian Wilde makes the case for adult stem cells in perhaps the most succinct manner possible.

As the author explains; “If you take the moral, political and ethical concerns off the table, the scientific issues alone confronting ESC research (according to many scientists) are in themselves, daunting. Before an ESC can be safely injected into a human being it must be proven safe in an animal study. In cases to date, animal subjects have experienced dangerous tumor growth and rejection by the body.”

He believes the public deserves balanced non-selective and un-biased reporting on both forms of stem cell research.

With a one to seven year life expectancy and 50% not making the five-year mark, heart failure is currently claiming the lives of 22 million victims world wide. Using a minimally invasive procedure using their own thigh muscle stem cells only once, patients have successfully transitioned within the FDA trials from near death to recovery. Documentation of these “no option” heart patient’s stories can be found in Miracle Stem Cell Heart Repair.

Why, asks Wilde, should it be headline world news that someday an embryonic stem cell might possibly heal a mouse heart but nowhere is there a headline that proclaims hundreds of actual living breathing people, (not mice) have already had their damaged hearts repaired with adult stem cells? Is this a case of selective reporting?

As many as five previous heart attacks were sustained by several of the patients whose stories were documented in the book.

“75% of your heart is not functioning, frankly I don’t know how you are even alive,” said one patient’s own physician.

The same patient was walking one mile and then two miles a day after six weeks and continues to do well two years after surgery following the one-time stem cell treatment with the patient’s own adult cells at the Arizona Heart Institute. The Myoheart heart failure study has now been opened to 450 more patients as treatment moves toward approval since the FDA was satisfied with the safety and clinical success of the trial’s first phase.

More than 72 diseases which included type I and II diabetes, several cancers, MS, Parkinson’s, traumatic brain injury, and blindness are currently treatable with adult stem cells. Corneal blindness is being cured at a rate of eight patients per month in Cincinnati and more than four hundred and fifty blind patients in India have been cured to date. Type II diabetes is being treated with a high rate of success inBrazil and Argentina using adult stem cells, and in similar fashion, a one-time injection of bone marrow stem cells to the pancreas as kept a type I diabetes patient in London insulin free for three years.

Following a single procedure in which stem cells from their own nasal olfactory cavity were harvested and injected into the areas of spinal lesion, one hundred five quadriplegic and paraplegic patients are beginning to walk (some with braces). Half of Dr. Lima’s patients are United States natives.

With these successes there is wonder in how anyone can argue for embryonic stem cells any more. But regardless, the debate continues. Before long, the cures will be mainstream and there won’t be a place or use for embryonic cells any longer. Perhaps that is what it will take to finally end the debate.

Japanese Goverment Allocates Funds for More Adult Stem Cell Research

Recent breakthroughs in stem cell research have produced embryonic stem cells from non-controversial adult skin cells. These same scientists are now being funded by a Japanese government agency which has decided to forge ahead with stem cell research.

Human embryos, aborted fetuses, and adult stem cells made up the only three options for stem cell research. But that is no longer the case.

After the scientists reported their amazing discovery of being able to create stem cells from human skin cells, a mere 2 weeks passed before the decision was made by the Japan Science and Technology Agency to release the funds.

Due to the fact that scientists will no longer need to create and destroy an embryo in order to extract stem cells, critics of stem cell research should tone down their protesting due to this discovery.

The cells can be used to treat many different parts of a person’s body depending on their injury or medical disease/condition. The fact that they can be converted into many different types of cell tissue after they are extracted makes the discovery particularly amazing.

The cells were converted to an embryo like state by injecting them with genes. Skin cells from the foreskin of a newborn and normal skin cells from a 36 year old woman’s face were utilized by the Japanese and U.S. research teams. Cartilage, fat, muscle, brain, and heart cells were among those that were created from the skin cells.

In order to determine if the newly programmed stem cells actually are what they appear to be more studies will be required say both research teams.

A shout has been echoing around the world due to the breakthrough.

“We’re on the way now,” said Dr. Michael Creer, director of laboratory medicine at St. Louis University and former director of the St. Louis Cord Blood Bank. “The opportunities are expanding enormously. What we think might work today could well change in the next few months … We still don’t fully understand or appreciate what is possible.”

Many people are jumping up and down with excitement with the possibility of finding treatments and cures for diseases or conditions that currently have limited treatment options. Experts say that the work is far from finished.

“People have to understand that we’re not ‘there’ yet,” said Dr. Steve Teitelbaum, a Washington University pathologist.

Significant treatments have already resulted from stem cell research. Certain eye conditions, cancer, and diabetes are among the conditions which are currently treatable using adult stem cells.